These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Renal protection by a dual ETA/ETB endothelin antagonist, L-754,142, after aortic cross-clamping in the dog. Krause SM; Walsh TF; Greenlee WJ; Ranaei R; Williams DL; Kivlighn SD J Am Soc Nephrol; 1997 Jul; 8(7):1061-71. PubMed ID: 9219155 [TBL] [Abstract][Full Text] [Related]
3. Effects of endothelin-1 and endothelin-1 receptor blockade on cardiac output, aortic pressure, and pulse wave velocity in humans. Vuurmans TJ; Boer P; Koomans HA Hypertension; 2003 Jun; 41(6):1253-8. PubMed ID: 12743011 [TBL] [Abstract][Full Text] [Related]
4. Biological role for the endothelin-A receptor in aortic cross-clamping. Stingo AJ; Clavell AL; Aarhus LL; Burnett JC Hypertension; 1993 Jul; 22(1):62-6. PubMed ID: 8319993 [TBL] [Abstract][Full Text] [Related]
5. Effects of endothelin-1 and endothelin-1-receptor blockade on renal function in humans. Vuurmans JL; Boer P; Koomans HA Nephrol Dial Transplant; 2004 Nov; 19(11):2742-6. PubMed ID: 15328386 [TBL] [Abstract][Full Text] [Related]
6. Improvement of renal dysfunction in dogs with endotoxemia by a nonselective endothelin receptor antagonist. Mitaka C; Hirata Y; Yokoyama K; Nagura T; Tsunoda Y; Amaha K Crit Care Med; 1999 Jan; 27(1):146-53. PubMed ID: 9934909 [TBL] [Abstract][Full Text] [Related]
7. Effect of Ro 61-1790, a selective endothelin-A receptor antagonist, on systemic and uterine hemodynamics and fetal oxygenation in sheep. McElvy S; Greenberg S; Baker RS; Khoury J; Clark KE Am J Obstet Gynecol; 2002 Jan; 186(1):55-60. PubMed ID: 11810085 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic administration of an endothelin-A receptor antagonist after acute ischemic renal failure dose-dependently improves recovery of renal function. Knoll T; Schult S; Birck R; Braun C; Michel MS; Bross S; Juenemann KP; Kirchengast M; Rohmeiss P J Cardiovasc Pharmacol; 2001 Apr; 37(4):483-8. PubMed ID: 11300661 [TBL] [Abstract][Full Text] [Related]
9. Endothelin B receptor-mediated vasoconstriction induced by endothelin A receptor antagonist. Zhang Y; Oliver JR; Horowitz JD Cardiovasc Res; 1998 Sep; 39(3):665-73. PubMed ID: 9861310 [TBL] [Abstract][Full Text] [Related]
10. Bosentan the mixed endothelin-A- and -B-receptor antagonist suppresses intrapericardial endothelin-1-induced ventricular arrhythmias. Horkay F; Gellér L; Kiss O; Szabó T; Vagó H; Kékesi V; Juhász-Nagy A; Merkely B J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S320-2. PubMed ID: 11078409 [TBL] [Abstract][Full Text] [Related]
11. Effects of Ro 47-0203 and PD155080 on the plasma kinetics, receptor binding and vascular effects of endothelin in the pig. Hemsén A; Modin A; Wanecek M; Malmström RE; Weitzberg E Eur J Pharmacol; 1996 Dec; 318(2-3):369-76. PubMed ID: 9016927 [TBL] [Abstract][Full Text] [Related]
12. Contribution of endogenous endothelin to large epicardial coronary artery tone in dogs and humans. Thorin E; Parent R; Ming Z; Lavallée M Am J Physiol; 1999 Aug; 277(2):H524-32. PubMed ID: 10444477 [TBL] [Abstract][Full Text] [Related]
13. Clazosentan, an endothelin receptor antagonist, prevents early hypoperfusion during the acute phase of massive experimental subarachnoid hemorrhage: a laser Doppler flowmetry study in rats. Schubert GA; Schilling L; Thomé C J Neurosurg; 2008 Dec; 109(6):1134-40. PubMed ID: 19035733 [TBL] [Abstract][Full Text] [Related]
14. Acute effects of an endothelin-1 receptor antagonist bosentan at different stages of heart failure in conscious dogs. Choussat R; Hittinger L; Barbe F; Maistre G; Carayon A; Crozatier B; Su J Cardiovasc Res; 1998 Sep; 39(3):580-8. PubMed ID: 9861300 [TBL] [Abstract][Full Text] [Related]
15. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? Spieker LE; Noll G; Ruschitzka FT; Lüscher TF J Am Coll Cardiol; 2001 May; 37(6):1493-505. PubMed ID: 11345356 [TBL] [Abstract][Full Text] [Related]
16. Chronic therapy with an ET(A/B) receptor antagonist in conscious dogs during progression of congestive heart failure. Intracellular Ca(2+) regulation and nitric oxide mediated coronary relaxation. Shen YT; Buie PS; Lynch JJ; Krause SM; Ma XL Cardiovasc Res; 2000 Nov; 48(2):332-45. PubMed ID: 11054479 [TBL] [Abstract][Full Text] [Related]
17. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. Roux S; Breu V; Giller T; Neidhart W; Ramuz H; Coassolo P; Clozel JP; Clozel M J Pharmacol Exp Ther; 1997 Dec; 283(3):1110-8. PubMed ID: 9399983 [TBL] [Abstract][Full Text] [Related]
18. Significant roles of endothelin-A- and -B-receptors in renal function in congestive heart failure. Ohnishi M; Wada A; Tsutamoto T; Sawaki M; Fujii M; Matsumoto T; Kinoshita M J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S140-3. PubMed ID: 11078360 [TBL] [Abstract][Full Text] [Related]
19. Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure. Brochu E; Lacasse S; Larivière R; Kingma I; Grose JH; Lebel M J Am Soc Nephrol; 1999 Jul; 10(7):1440-6. PubMed ID: 10405199 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of endothelin-1 by the competitive ET(A) receptor antagonist Ro 61-1790 reduces lesion volume after cold injury in the rat. Görlach C; Hortobágyi T; Hortobágyi S; Benyó Z; Wahl M Pflugers Arch; 2001 Mar; 441(6):844-9. PubMed ID: 11316270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]